Trial Profile

Dose escalation study of APL-3007

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APL 3007 (Primary)
Indications Unspecified
Focus Adverse reactions

Most Recent Events

05 Nov 2024 According an Apellis Pharmaceuticals media release, topline data of this trial is expected in Q1 2025.
01 Mar 2024 New trial record
27 Feb 2024 According an Apellis Pharmaceuticals media release, topline data of this trial is expected in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com